Randomized trial of radiotherapy versus radiotherapy plus metronidazole for the treatment metastatic cancer to brain
dc.contributor.author | Eyre, Harmon J. | en_US |
dc.contributor.author | Ohlsen, Joel D. | en_US |
dc.contributor.author | Frank, Jess | en_US |
dc.contributor.author | LoBuglio, Albert F. | en_US |
dc.contributor.author | Mansfield, C. M. | en_US |
dc.contributor.author | McCracken, Joseph D. | en_US |
dc.contributor.author | Weatherall, T. J. | en_US |
dc.date.accessioned | 2006-09-11T15:59:31Z | |
dc.date.available | 2006-09-11T15:59:31Z | |
dc.date.issued | 1984-12 | en_US |
dc.identifier.citation | Eyre, Harmon J; Ohlsen, Joel D; Frank, Jess; LoBuglio, Albert F; McCracken, Joseph D; Weatherall, T J; Mansfield, C M; (1984). "Randomized trial of radiotherapy versus radiotherapy plus metronidazole for the treatment metastatic cancer to brain." Journal of Neuro-Oncology 2(4): 325-330. <http://hdl.handle.net/2027.42/45380> | en_US |
dc.identifier.issn | 0167-594X | en_US |
dc.identifier.issn | 1573-7373 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/45380 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=6397578&dopt=citation | en_US |
dc.description.abstract | One hundred sixteen eligible patients with metastatic cancer to the brain were randomized to receive either radiotherapy 3000 rad/ 10 fractions (treatment 1) or the same radiotherapy plus metronidazole 6 gm/m 2 (treatment 2). One hundred eleven patients were either fully or partially evaluable. The response rates (CR + PR) and survival showed no significant differences between treatments. Treatment 1: CR + PR 24%, median survival 14 weeks, Treatment 2: CR + PR 27%, median survival 12 weeks. There were no differences observed in response rates based on primary tumor site, neurologic performance status, or extent of metastatic disease. Metronidazole therapy was associated with substantial nausea and vomiting but no neurotoxicity was observed. Oral metronidazole given every other day during radiation therapy provided no clinical benefit for patients with brain metastases compared to radiotherapy alone. | en_US |
dc.format.extent | 366601 bytes | |
dc.format.extent | 3115 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Martinus Nijhoff, The Hague/Kluwer Academic Publishers; Martinus Nijhoff Publishers ; Springer Science+Business Media | en_US |
dc.subject.other | Medicine & Public Health | en_US |
dc.subject.other | Brain | en_US |
dc.subject.other | Radiotherapy | en_US |
dc.subject.other | Metastases | en_US |
dc.subject.other | Oncology | en_US |
dc.title | Randomized trial of radiotherapy versus radiotherapy plus metronidazole for the treatment metastatic cancer to brain | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Public Health | en_US |
dc.subject.hlbsecondlevel | Otolaryngology | en_US |
dc.subject.hlbsecondlevel | Ophthalmology | en_US |
dc.subject.hlbsecondlevel | Oncology and Hematology | en_US |
dc.subject.hlbsecondlevel | Obstetrics and Gynecology | en_US |
dc.subject.hlbsecondlevel | Neurosciences | en_US |
dc.subject.hlbsecondlevel | Internal Medicine and Specialties | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | University of Michigan Medical Center, USA | en_US |
dc.contributor.affiliationother | University of Utah Medical Center, USA | en_US |
dc.contributor.affiliationother | Brook Army Medical Center, USA | en_US |
dc.contributor.affiliationother | Tulane University, USA | en_US |
dc.contributor.affiliationother | University of Kansas Medical Center, USA | en_US |
dc.contributor.affiliationother | Southwest Oncology Group Biostatistical Center, USA | en_US |
dc.contributor.affiliationother | University of Utah Medical Center, USA | en_US |
dc.contributor.affiliationumcampus | Ann Arbor | en_US |
dc.identifier.pmid | 6397578 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/45380/1/11060_2004_Article_BF00178115.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1007/BF00178115 | en_US |
dc.identifier.source | Journal of Neuro-Oncology | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.